HIV感染合并晚期癌症患者免疫检查点抑制剂治疗的安全性与疗效:系统综述
该系统综述检索PubMed及2016至2018年主要肿瘤与艾滋病学会年会摘要,纳入73例接受免疫检查点抑制剂(ICI)治疗的HIV感染晚期癌症患者,多数为病例报告。ICI总体耐受良好,≥3级免疫相关不良事件见于6/70例(8.6%),非小细胞肺癌、黑色素瘤和卡波西肉瘤客观缓解率分别为30%、27%和63%。
要点
- 73例HIV感染晚期癌症患者接受ICI,≥3级免疫相关不良事件见于6/70例(8.6%)。
- 已知配对HIV载量的34例中,治疗前载量检测不到的28例中26例(93%)治疗后仍保持抑制。
- 客观缓解率:非小细胞肺癌30%、黑色素瘤27%、卡波西肉瘤63%。
核心结论
- HIV感染患者晚期癌症接受ICI治疗未观察到新的安全性信号。
- ICI可能是该人群安全有效的治疗选择。
- 多项正在进行的前瞻性临床试验将进一步阐明ICI在该人群中的安全性与疗效。
研究设计与样本
- 系统综述,按PRISMA指南实施。
- 2018年4月16日检索PubMed,关键词为HIV及美国FDA批准的ICI名称(ipilimumab、nivolumab、pembrolizumab、avelumab、atezolizumab、durvalumab)。
- 同时复习2016至2018年主要肿瘤与艾滋病学会年会摘要和壁报。
- 纳入HIV感染并接受ICI治疗晚期癌症的患者,共从13篇文章(11篇病例报告和2篇病例系列)和4篇会议摘要中识别73例患者。
主要发现
- 73例患者中66例(90.4%)为男性,平均年龄56.1岁(范围30.0-77.0岁)。
- 62例接受抗PD-1治疗,6例接受抗CTLA-4治疗,4例接受抗PD-1/CTLA-4治疗,1例接受ipilimumab序贯nivolumab治疗。
- ≥3级免疫相关不良事件见于6/70例(8.6%)。
- 已知配对治疗前后HIV载量的34例中,治疗前载量检测不到的28例中26例(93%)治疗后HIV仍保持抑制。
- 25例有配对治疗前后CD4细胞计数的患者中,计数增加(平均[SD]变化12.3[28.5]/μL)。
关键数值与推荐
- ≥3级免疫相关不良事件:6/70例(8.6%)。
- 治疗前HIV载量检测不到的28例中26例(93%)治疗后仍保持抑制。
- CD4计数平均(SD)变化12.3(28.5)/μL。
- 客观缓解率:非小细胞肺癌30%、黑色素瘤27%、卡波西肉瘤63%。
临床怎么用
- 作者认为ICI可能是HIV感染晚期癌症患者安全有效的治疗选择。
- 作者指出多项正在进行的前瞻性临床试验将进一步阐明ICI在该人群中的安全性与疗效。
局限性
- 纳入证据主要来自病例报告和病例系列(13篇文章中11篇病例报告、2篇病例系列)及4篇会议摘要。
- 作者指出需正在进行的prospective临床试验进一步阐明ICI在该人群中的安全性与疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with HIV infection are at increased risk for cancer. Cancer is the leading cause of death among non-AIDS-defining illnesses in these patients. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of cancer. However, clinical trials of ICIs have historically excluded patients with HIV infection. The safety and efficacy profile of ICIs is unknown in this underrepresented population. OBJECTIVE: To summarize results on the safety and efficacy of ICI therapy in HIV-infected patients with advanced-stage cancer. EVIDENCE REVIEW: This systematic review was conducted in accordance with PRISMA guidelines. A literature search of PubMed was performed on April 16, 2018, using the keyword HIV and the names of ICIs approved by the US Food and Drug Administration (ipilimumab, nivolumab, pembrolizumab, avelumab, atezolizumab, and durvalumab). Patients with HIV infection who were being treated with ICIs for advanced-stage cancer were included. In addition, abstracts and posters from major oncology and AIDS society annual meetings from 2016 through 2018 were reviewed. FINDINGS: Seventy-three patients (66 [90.4%] male; mean age, 56.1 years [range, 30.0-77.0 years]) were identified from 13 articles (11 case reports and 2 case series) and 4 meeting abstracts. Sixty-two patients were treated with anti-programmed cell death 1 (anti-PD-1) therapy, 6 with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) therapy, 4 with anti-PD-1/CTLA-4 therapy, and 1 with sequential ipilimumab and nivolumab therapy. Immune checkpoint inhibitor therapy was generally well tolerated, with grade 3 or higher immune-related adverse events noted in 6 of 70 patients (8.6%). Among 34 patients with known paired pretreatment and posttreatment HIV loads, HIV remained suppressed in 26 of the 28 (93%) with undetectable HIV load. Among the 25 with paired pretreatment and posttreatment CD4 cell counts, the counts increased (mean [SD] change, 12.3 [28.5] /μL). Objective response rates were 30% for non-small cell lung cancer, 27% for melanoma, and 63% for Kaposi sarcoma. CONCLUSIONS AND RELEVANCE: Immune checkpoint inhibitor therapy for the treatment of advanced-stage cancer in patients with HIV infection was associated with no new safety signals. Immune checkpoint inhibitors may be a safe and efficacious treatment option in this patient population. Several ongoing prospective clinical trials will shed further light on the safety and efficacy of ICI therapy in HIV-infected patients with cancer.
引用
- Cook MR, Kim C. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019. PMID: 30730549. doi:10.1001/jamaoncol.2018.6737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。